
Synthetic Gestalt is pioneering the integration of biotechnology and AI to revolutionize drug discovery. The company develops autonomous systems that leverage proprietary machine learning models to identify valuable molecules and lead compounds for drug development. By collaborating with leading research institutions and pharmaceutical companies, Synthetic Gestalt aims to automate the drug discovery pipeline, significantly accelerating the process of bringing new drugs to market. Their unique approach positions them at the forefront of the next industrial revolution in life sciences, with a strong emphasis on innovation and societal impact.

Synthetic Gestalt is pioneering the integration of biotechnology and AI to revolutionize drug discovery. The company develops autonomous systems that leverage proprietary machine learning models to identify valuable molecules and lead compounds for drug development. By collaborating with leading research institutions and pharmaceutical companies, Synthetic Gestalt aims to automate the drug discovery pipeline, significantly accelerating the process of bringing new drugs to market. Their unique approach positions them at the forefront of the next industrial revolution in life sciences, with a strong emphasis on innovation and societal impact.
What they do: AI-driven machine learning models and software to accelerate drug discovery and automate life-science research
Founded / HQ: 2018; London, United Kingdom
Team size (public profile): 11-50 employees (profiles list ranges; one snapshot: 18)
Latest disclosed funding: Series A (announced Sep 29, 2021 per funding profile entries)
Known investors: The Future Fund; MITSUI SUMITOMO INSURANCE Venture Capital (MSIVC); Incubate Fund; Headline Asia; additional investors listed in some profiles
Drug discovery and life-science R&D automation
2018
Biotechnology
Series A announced Sep 29, 2021; investors listed include The Future Fund, MSIVC, Incubate Fund, Headline Asia
“Investors include The Future Fund; MITSUI SUMITOMO INSURANCE Venture Capital (MSIVC); Incubate Fund; Headline Asia; Amazon Web Services; The Future Fund listed across profiles”
| Company |
|---|